Navigation Links
Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study

th migraine. An innovative, two-stage, adaptive dose-ranging design formulated through computer simulation was used to facilitate optimal dose selection.

A total of 420 adult patients who experienced migraine attacks, as defined by the International Headache Society criteria, were randomized (330 took drug) to treat a moderate or severe migraine attack with MK-0974 given orally at doses of 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, or 600 mg, or rizatriptan 10 mg, or placebo. Patients enrolled were primarily female (89 percent) with an average age of 41 years. Most treated headaches were moderate in baseline severity and did not have aura.

The first stage of the study evaluated all doses of MK-0974 with rizatriptan and placebo. When a preset number of migraine attacks were treated, an interim efficacy analysis was conducted resulting in dropping the four lowest doses of MK-0974 based on a pre-specified algorithm. The second stage of the study continued with randomization of patients to MK-0974 300 mg, 400 mg or 600 mg or to rizatriptan 10 mg or placebo.

Overall treatment effect was analyzed by comparing the average response of the MK-0974 treatment groups (300 mg, 400 mg and 600 mg) to the response observed in the placebo group. The study was not powered to detect differences between the individual doses of MK-0974 or between MK-0974 doses and rizatriptan.

Study results

For the primary endpoint, the overall treatment effect of MK-0974 in relieving migraine pain (reduction from severe or moderate to mild or none) two hours after dosing was significant compared to placebo (p=0.015). The proportion of patients reporting pain relief at two hours for those treated with MK-0974 was 68.1 percent (300 mg; n=38), 48.2 percent (400 mg; n=45) and 67.5 percent (600 mg, n=40); and 69.5 percent for rizatriptan (n=34) compared to 46.3 percent for placebo (n=115).

A similar pattern was observed for secondary measures in which the overall
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
4. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
5. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
(Date:1/15/2014)... Jan. 15, 2014 Sono-Tek Corporation (OTC BB: SOTK) today ... 30, 2013, compared to sales of $2,202,000 for the prior ... this quarter has also shown growth over the preceding quarter,s ... of this fiscal year. Markets that experienced sales increases over ...
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ... Consumables Market - Global Industry Analysis, Size, Share, Growth, ... their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... are used on patients in order to treat dental ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Novation, the leading ... awarded several new IT value-added reseller (VAR) national contracts ... IT goods and services at lower costs. These include ... services such as initiative assistance and ongoing IT consulting ...
Breaking Medicine Technology:Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2
... Niiki Pharma Inc. announced today that it has ... clinical trial of its lead product, NKP-1339. NKP-1339 is ... tumor survival and anti-apoptosis factor. The NKP-1339 ... in patients with advanced solid tumors resistant to multiple, ...
... 2012 ULURU Inc. (NYSE AMEX: ULU ... European license for Altrazeal® to include the Middle East and ... the territory, Helmut Kerschbaumer Chairman of Melmed Holdings AG, stated, ... marketing to the various sectors in these markets. We have ...
Cached Medicine Technology:Niiki Pharma Announces the Completion of Phase I Dose Escalation for First-in-Man Anti-Cancer Agent NKP-1339 2ULURU Inc. Extends the European Altrazeal® License to Include the Middle East and Africa 2
(Date:7/11/2014)... With the arrival of summer, VisitandCare.com today ... and hair transplant procedures, up 80 percent from July ... medical tourism destinations, the company is helping patients take ... achieve the look they have always desired. , ... in the medical tourism industry, VisitandCare.com is comprised of ...
(Date:7/11/2014)... Steven Reinberg HealthDay ... Stress, hostility and depression may increase the risk for stroke, ... seemed to raise the risk of a stroke or ... found that stress apparently raised stroke or TIA risk by ... A TIA is a mini-stroke caused by a temporary blockage ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Fadhits.com, the ... its elegant assortment of lace holiday dresses . ... products are now offered at discounted prices, up to ... website can enjoy this special offer. , Fadhits.com ... and special occasion dresses for the global clients. All ...
(Date:7/11/2014)... San Francisco shows that an "expressive therapy" group ... living with HIV disclose their health status and ... and quality of their relationships., "Medication alone is ... L. Machtinger, MD, director of the Women,s HIV ... patients are on effective antiretroviral therapy but far ...
(Date:7/11/2014)... CA (PRWEB) July 11, 2014 Bedros Keuilian ... expert; a title he’s earned by founding the fast-selling fitness ... on marketing their businesses. He works with successful boot camp ... blog post on the traits of the most successful boot ... share three important qualities. , “I’ve worked with and coached ...
Breaking Medicine News(10 mins):Health News:VisitandCare.com Reports Increase in Cosmetic and Hair Transplant Procedures for Men 2Health News:VisitandCare.com Reports Increase in Cosmetic and Hair Transplant Procedures for Men 3Health News:Stress, Depression May Boost Stroke Risk, Study Finds 2Health News:Stress, Depression May Boost Stroke Risk, Study Finds 3Health News:Elegant Lace Holiday Dresses Released by Fadhits.com 2Health News:'Expressive therapy" intervention assists women living with HIV 2Health News:Fitness Boot Camp Marketing Expert Bedros Keuilian Shares the Top Three Traits of Successful Boot Camp Owners 2Health News:Fitness Boot Camp Marketing Expert Bedros Keuilian Shares the Top Three Traits of Successful Boot Camp Owners 3
... a leader in the field of clinical supply chain management, announced today ... the MHS Board of Directors. www.mhsinc.com , ... Fairfield, Connecticut ... a leader in the field of clinical supply chain management, announced today ...
... A team of Slimband employees successfully competed in the 19th Annual Canada Life ... , ... ON (PRWEB) April 22, 2009-- A team of Slimband employees successfully ... took place on April 16th. The CN Tower Climb is a demanding ...
... Committee,s (SASC) report on detainee abuse, Physicians for Human Rights (PHR) ... for the Central Intelligence Agency (CIA) and Department of Defense (DoD), ... , ... (Vocus) April 21, 2009 -- In the wake ...
... Only two percent of hospitals nationwide receive Magnet ... Center (ANCC) has announced that Baylor University ... earned re-designation as a Magnet hospital, effective immediately. ... been designated at a Magnet hospital, and merely ...
... to Save Millions of Plastic Bags from LandfillsITASCA, Ill., ... drug retailer, is partnering with WFLD FOX Chicago this ... Reuse" challenge, an initiative aimed at increasing consumer use ... plastic bags from ending up in area landfills. The ...
... 21 Carl Icahn announced today that he had sent the following letter to Joseph C. Cook, ... AMLN ) concerning recent discussions between Mr. Icahn and Messrs. Cook and Wilson , , ... ... April 21, 2009, Joseph Cook, Jr., Chairman of ...
Cached Medicine News:Health News:Daniel C. Lubin Joins Management Health Solutions, Inc. Board of Directors 2Health News:Slimband™ Team Competes in CN Tower Climb and Helps Fight Against Global Warming 2Health News:PHR: After Senate Report, Psychologists Who Tortured Must Be Held to Account 2Health News:PHR: After Senate Report, Psychologists Who Tortured Must Be Held to Account 3Health News:PHR: After Senate Report, Psychologists Who Tortured Must Be Held to Account 4Health News:Baylor Dallas Nationally Recognized for Nursing Excellence 2Health News:JEWEL-OSCO & FOX Chicago Launch 'Choose to Reuse' Bag Program 2Health News:JEWEL-OSCO & FOX Chicago Launch 'Choose to Reuse' Bag Program 3Health News:Icahn Responds to Cook and Wilson 2Health News:Icahn Responds to Cook and Wilson 3Health News:Icahn Responds to Cook and Wilson 4
Easy-to-use system for displaced femoral neck fractures in the low demand patient....
The APR Hip System offers a complete line of stems to precisely match patients' anatomic needs and address surgeon preferences....
Dual offset femoral stems, hip stems that provide unique and competitive features....
The P.S.L. stem is manufactured from cobalt chrome and is available with or without porous coating to give the surgeon the option of utilizing either the cementless of cemented technique at his or he...
Medicine Products: